Gilead Sciences Portfolio holdings
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
Top Buys
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merus
MRUS
|
+$42.6M |
| 2 |
Tango Therapeutics
TNGX
|
+$40.8M |
| 3 |
Cypherpunk Technologies Inc
CYPH
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Arcus Biosciences
RCUS
$2.32B
| $749M | 38.69% |
31,424,760
| – | – |
2024 Q4
4 quarters
|
|
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.13B
| $551M | 28.45% |
16,707,477
| – | – |
2024 Q4
4 quarters
|
|
3
DELISTED
Arcellx
ACLX
| $438M | 22.64% |
6,720,803
| – | – |
2024 Q4
4 quarters
|
|
4
Assembly Biosciences
ASMB
$410M
| $153M | 7.92% |
4,505,391
| – | – |
2024 Q4
4 quarters
|
|
5
Kyverna Therapeutics
KYTX
$351M
| $38.8M | 2% |
4,126,119
| – | – |
2024 Q4
4 quarters
|
|
6
Xilio Therapeutics
XLO
$52.8M
| $5.83M | 0.3% |
650,389
| – | – |
2024 Q4
4 quarters
|
|
|
7
Cypherpunk Technologies Inc
CYPH
$321M
| – | – |
-5,319,148
| Closed | -$2.41M | – |
|
|
8
DELISTED
Merus
MRUS
| – | – |
-452,527
| Closed | -$42.6M | – |
|
|
9
Tango Therapeutics
TNGX
$3.83B
| – | – |
-4,854,443
| Closed | -$40.8M | – |
|
Similar funds
Gilead Sciences's Q4 2025 Portfolio in Review
As of Q4 2025, Gilead Sciences held 9 positions worth $1.94B, up 8% from $1.79B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Gilead Sciences withdrew a net $85.8M in Q4 2025, closing 3 positions. Its most notable exit was Merus, an estimated $42.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
- Gilead Sciences fully exited Merus in Q4 2025, selling an estimated $42.6M.
- Gilead Sciences's ten largest holdings make up 100% of its $1.94B portfolio in Q4 2025.
- Gilead Sciences opened 0 new positions and closed 3 in Q4 2025.
- Gilead Sciences's portfolio value rose 8% quarter-over-quarter to $1.94B.
Based on Gilead Sciences's 13F filing for Q4 2025, filed 12 Feb 2026.